Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

U.S. stocks closed another record-setting week with a muted performance. The S&P 500 edged down by 0.1% Friday from its ...

Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...

The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...

Also, the Aug core PCE price index, the Fed’s preferred inflation gauge, came in right on expectations, knocking T-note yields lower and supporting stocks. An upward revision to the University of ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...